Method of promoting bone growth by an anti-activin A antibody
In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density.
1. A method for promoting bone growth, increasing bone density, or increasing bone strength, the method comprising administering to a subject in need thereof an effective amount of an anti-activin A antibody.
2. The method of claim 1 , wherein the anti-activin A antibody is a monoclonal antibody.
3. The method of claim 1 , wherein the method is for promoting bone growth in a subject in need thereof.
4. The method of claim 1 , wherein the method is for increasing bone density in a subject in need thereof.
5. The method of claim 1 , wherein the method is for increasing bone strength in a subject in need thereof.
6. The method of claim 1 , wherein the method further comprises administering a second bone-active agent.
7. The method of claim 6 , wherein the bone-active agent is selected from a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement.
8. The method of claim 1 , wherein the anti-activin A antibody is a humanized or fully human antibody.
9. A method for treating a bone-related disorder, the method comprising administering to a subject in need thereof an effective amount of an anti-activin A antibody, wherein the bone-related disorder is associated with low bone density or decreased bone strength.
10. The method of claim 9 , wherein the bone-related disorder is primary osteoporosis.
11. The method of claim 9 , wherein the bone-related disorder is post-menopausal osteoporosis.
12. The method of claim 9 wherein the method further comprises administering a second bone-active agent.
13. The method of claim 12 , wherein the bone-active agent is selected from the group consisting of: a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement.
14. The method of claim 9 , wherein the bone-related disorder is secondary osteoporosis.
15. The method of claim 9 , wherein the bone-related disorder is hypogonadal bone loss.
16. The method of claim 9 , wherein the subject has a cancer that is associated with bone loss.
17. The method of claim 9 , wherein the subject is the recipient of a cancer treatment regimen than is associated with bone loss.
18. The method of claim 9 , wherein the bone-related disorder is bone metastases.
19. The method of claim 9 , wherein the bone-related disorder is multiple myeloma.
20. The method of claim 9 , wherein the bone-related disorder is Paget's disease.
21. The method of claim 9 , wherein the subject has a cancer that is associated with bone metastases.
22. The method of claim 21 , wherein the subject is positive for an indicator of loss of bone density, bone resorption, or bone metastases.
23. The method of claim 9 , wherein the anti-activin A antibody is a monoclonal antibody.
24. The method of claim 9 , wherein the anti-activin A antibody is a humanized or fully human antibody.
25. A method for promoting bone growth and inhibiting bone resorption in a patient, the method comprising administering to a subject in need thereof an effective amount of an anti-activin A antibody.
26. The method of claim 25 , wherein the method causes less than a 10% increase in the patient's skeletal muscle mass.
27. The method of claim 25 , wherein the method further comprises administering a second bone-active agent.
28. The method of claim 27 , wherein the bone-active agent is selected from a bisphosphonate, an estrogen, a selective estrogen-receptor modulator, a parathyroid hormone, a calcitonin, a calcium supplement, and a vitamin D supplement.
29. The method of claim 25 , wherein the anti-activin A antibody is a monoclonal antibody.
30. The method of claim 25 , wherein the anti-activin A antibody is a humanized or fully human antibody.